LivaNova PLC (NASDAQ:LIVN) Files An 8-K Results of Operations and Financial ConditionItem 2.02 Results of Operations and Financial Condition.
On August 9, 2017, LivaNova PLC (the “Company”) issued a press release announcing financial results for the second quarter ended June 30, 2017. The purpose of the Form 8-K/A is to correct a typographical error in the table entitled LivaNova PLC and Subsidiaries Condensed Consolidated Balance Sheets. A copy of the Company’s amended press release is furnished as Exhibit 99.1 on this Current Report on Form 8-K/A.
The information in Item 2.02 of this report is being furnished, not filed, for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and to General Instruction B.2 of Form 8-K, will not be incorporated by reference into any filing under the Securities Act of 1933, as amended, unless specifically identified therein as being incorporated therein by reference.
Item 9.01 Financial Statements and Exhibits.
Amended Press Release issued by LivaNova PLC dated August 9, 2017
LivaNova PLC ExhibitEX-99.1 2 amended2qfy17earningspress.htm AMENDED EARNINGS PRESS RELEASE Exhibit NEWS RELEASELivaNova Reports Second Quarter 2017 ResultsLondon,…To view the full exhibit click
About LivaNova PLC (NASDAQ:LIVN)
LivaNova PLC is a medical technology company. The Company operates through three segments: Cardiac Surgery, Cardiac Rhythm Management (CRM) and Neuromodulation. The Cardiac Surgery business unit is engaged in the development, production and sale of cardiovascular surgery products, including oxygenators, heart-lung machines, perfusion tubing systems and systems for autotransfusion and autologous blood washing. The CRM business unit develops, manufactures and markets products for the diagnosis, treatment and management of heart rhythm disorders and heart failure. CRM offers products, including leads and delivery systems, and information systems. The Neuromodulation business unit designs, develops and markets neuromodulation-based medical devices for the treatment of epilepsy and depression. Through the Neuromodulation business unit, the Company markets its implantable VNS Therapy systems that deliver vagus nerve stimulation therapy for the treatment of epilepsy and depression.